vs

Side-by-side financial comparison of OPKO HEALTH, INC. (OPK) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

OPKO HEALTH, INC. is the larger business by last-quarter revenue ($148.5M vs $127.1M, roughly 1.2× Zai Lab Ltd). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs -19.2%). Zai Lab Ltd produced more free cash flow last quarter ($-26.7M vs $-28.6M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs -7.5%).

OPKO Health, Inc. is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

OPK vs ZLAB — Head-to-Head

Bigger by revenue
OPK
OPK
1.2× larger
OPK
$148.5M
$127.1M
ZLAB
Growing faster (revenue YoY)
ZLAB
ZLAB
+36.3% gap
ZLAB
17.1%
-19.2%
OPK
More free cash flow
ZLAB
ZLAB
$1.9M more FCF
ZLAB
$-26.7M
$-28.6M
OPK
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
-7.5%
OPK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OPK
OPK
ZLAB
ZLAB
Revenue
$148.5M
$127.1M
Net Profit
$-31.3M
Gross Margin
43.1%
51.0%
Operating Margin
-25.8%
-54.6%
Net Margin
-21.1%
Revenue YoY
-19.2%
17.1%
Net Profit YoY
-322.8%
EPS (diluted)
$-0.04
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OPK
OPK
ZLAB
ZLAB
Q4 25
$148.5M
$127.1M
Q3 25
$151.7M
$115.4M
Q2 25
$156.8M
$109.1M
Q1 25
$150.0M
$105.7M
Q4 24
$183.6M
$108.5M
Q3 24
$173.6M
$101.8M
Q2 24
$182.2M
$100.1M
Q1 24
$173.7M
$87.1M
Net Profit
OPK
OPK
ZLAB
ZLAB
Q4 25
$-31.3M
Q3 25
$21.6M
$-36.0M
Q2 25
$-148.4M
$-40.7M
Q1 25
$-67.6M
$-48.4M
Q4 24
$14.0M
Q3 24
$24.9M
$-41.7M
Q2 24
$-10.3M
$-80.3M
Q1 24
$-81.8M
$-53.5M
Gross Margin
OPK
OPK
ZLAB
ZLAB
Q4 25
43.1%
51.0%
Q3 25
32.9%
59.5%
Q2 25
31.5%
60.6%
Q1 25
28.4%
63.6%
Q4 24
46.1%
61.5%
Q3 24
23.1%
64.1%
Q2 24
28.4%
64.9%
Q1 24
24.2%
61.4%
Operating Margin
OPK
OPK
ZLAB
ZLAB
Q4 25
-25.8%
-54.6%
Q3 25
31.7%
-42.3%
Q2 25
-38.3%
-50.3%
Q1 25
-44.8%
-53.3%
Q4 24
-18.0%
-62.6%
Q3 24
8.2%
-66.6%
Q2 24
-33.9%
-76.0%
Q1 24
-41.2%
-80.7%
Net Margin
OPK
OPK
ZLAB
ZLAB
Q4 25
-21.1%
Q3 25
14.3%
-31.2%
Q2 25
-94.7%
-37.3%
Q1 25
-45.1%
-45.8%
Q4 24
7.6%
Q3 24
14.3%
-40.9%
Q2 24
-5.7%
-80.2%
Q1 24
-47.1%
-61.4%
EPS (diluted)
OPK
OPK
ZLAB
ZLAB
Q4 25
$-0.04
$-0.05
Q3 25
$0.03
$-0.03
Q2 25
$-0.19
$-0.04
Q1 25
$-0.10
$-0.04
Q4 24
$0.02
$-0.09
Q3 24
$0.03
$-0.04
Q2 24
$-0.01
$-0.08
Q1 24
$-0.12
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OPK
OPK
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$364.4M
$689.6M
Total DebtLower is stronger
$344.0M
Stockholders' EquityBook value
$1.3B
$715.5M
Total Assets
$1.9B
$1.2B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OPK
OPK
ZLAB
ZLAB
Q4 25
$364.4M
$689.6M
Q3 25
$412.0M
$717.2M
Q2 25
$267.3M
$732.2M
Q1 25
$428.8M
$757.3M
Q4 24
$426.6M
$779.7M
Q3 24
$400.1M
$616.1M
Q2 24
$40.6M
$630.0M
Q1 24
$75.6M
$650.8M
Total Debt
OPK
OPK
ZLAB
ZLAB
Q4 25
$344.0M
Q3 25
$344.2M
Q2 25
$343.3M
Q1 25
$439.2M
Q4 24
$437.2M
Q3 24
$441.0M
Q2 24
$201.9M
Q1 24
$350.1M
Stockholders' Equity
OPK
OPK
ZLAB
ZLAB
Q4 25
$1.3B
$715.5M
Q3 25
$1.3B
$759.9M
Q2 25
$1.3B
$791.7M
Q1 25
$1.3B
$810.8M
Q4 24
$1.4B
$840.9M
Q3 24
$1.4B
$667.7M
Q2 24
$1.4B
$704.2M
Q1 24
$1.3B
$762.2M
Total Assets
OPK
OPK
ZLAB
ZLAB
Q4 25
$1.9B
$1.2B
Q3 25
$2.0B
$1.2B
Q2 25
$2.0B
$1.2B
Q1 25
$2.1B
$1.2B
Q4 24
$2.2B
$1.2B
Q3 24
$2.3B
$985.3M
Q2 24
$2.0B
$987.4M
Q1 24
$2.0B
$988.4M
Debt / Equity
OPK
OPK
ZLAB
ZLAB
Q4 25
0.27×
Q3 25
0.26×
Q2 25
0.26×
Q1 25
0.33×
Q4 24
0.32×
Q3 24
0.31×
Q2 24
0.14×
Q1 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OPK
OPK
ZLAB
ZLAB
Operating Cash FlowLast quarter
$-25.9M
$-26.0M
Free Cash FlowOCF − Capex
$-28.6M
$-26.7M
FCF MarginFCF / Revenue
-19.3%
-21.0%
Capex IntensityCapex / Revenue
1.8%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-190.8M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OPK
OPK
ZLAB
ZLAB
Q4 25
$-25.9M
$-26.0M
Q3 25
$-34.6M
$-32.0M
Q2 25
$-83.4M
$-31.0M
Q1 25
$-34.6M
$-61.7M
Q4 24
$-44.4M
$-55.8M
Q3 24
$-77.1M
$-26.8M
Q2 24
$-26.4M
$-42.2M
Q1 24
$-35.6M
$-90.1M
Free Cash Flow
OPK
OPK
ZLAB
ZLAB
Q4 25
$-28.6M
$-26.7M
Q3 25
$-37.8M
$-35.0M
Q2 25
$-86.7M
$-33.9M
Q1 25
$-37.7M
$-63.2M
Q4 24
$-49.8M
$-58.4M
Q3 24
$-85.0M
$-28.2M
Q2 24
$-33.7M
$-42.9M
Q1 24
$-40.0M
$-91.1M
FCF Margin
OPK
OPK
ZLAB
ZLAB
Q4 25
-19.3%
-21.0%
Q3 25
-24.9%
-30.4%
Q2 25
-55.3%
-31.1%
Q1 25
-25.2%
-59.9%
Q4 24
-27.1%
-53.8%
Q3 24
-49.0%
-27.7%
Q2 24
-18.5%
-42.9%
Q1 24
-23.0%
-104.5%
Capex Intensity
OPK
OPK
ZLAB
ZLAB
Q4 25
1.8%
0.5%
Q3 25
2.1%
2.6%
Q2 25
2.1%
2.6%
Q1 25
2.1%
1.5%
Q4 24
2.9%
2.4%
Q3 24
4.6%
1.3%
Q2 24
4.0%
0.7%
Q1 24
2.6%
1.1%
Cash Conversion
OPK
OPK
ZLAB
ZLAB
Q4 25
Q3 25
-1.60×
Q2 25
Q1 25
Q4 24
-3.17×
Q3 24
-3.10×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OPK
OPK

Services$71.1M48%
Transfer Of Intellectual Property And Other$33.7M23%
IE$22.1M15%
Rayaldee$8.8M6%
Barda Agreement$6.8M5%
MX$6.3M4%

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons